![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Intergalactic’s non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA which relies on a cellfree manufacturing process; and 2) COMET, a clinically advanced, pulsed electric field focal gene therapy delivery system.
Lead Product(s): Non-viral Based Gene Therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Intergalactic Therapeutics
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 07, 2021
Details:
ATP has committed $40 million in Series A funding to advance Aulos' lead molecule from preclinical stage through clinical proof of concept, with human trials expected to start later this year.
Lead Product(s): Monoclonal antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Aulos
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 08, 2021